Health
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Gelclair® is the company's third commercialized prescription product","length":80,"tagName":"p"},{"type":"text","content":"Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force","length":238,"tagName":"p"},{"type":"text","content":"Napo's core target patient audiences for Gelclair are head and neck cancer patients and bone marrow transplant patients","length":123,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") is exhibiting at the 50th anniversary Oncology Nursing Society (ONS) Congress taking place April 9-13, 2025 in Denver, Colorado as part of ongoing commercial activities for Gelclair.","length":374,"tagName":"p"},{"type":"text","content":""We have expanded our footprint beyond HIV-related supportive care to include cancer-related supportive care, and our recent in-licensing of the FDA-approved oral mucositis product Gelclair is a first building block," said Lisa Conte, Jaguar's president and CEO.","length":276,"tagName":"p"},{"type":"text","content":""Cancer is chaotic, because patients feel a loss of control - over their life, their treatment, and their supportive care needs," said Conte. "Jaguar's mission is to change patients' lives for the better, especially in the area of supportive care for complex disease states like cancer. We look forward to driving awareness among the oncology nursing community at ONS about Gelclair. Oral mucositis, also called "chemo mouth," is among the most common, painful, and debilitating cancer treatment-related side effects, and it is undertreated and underappreciated. We believe we can help cancer patients by giving them a supportive care product for oral mucositis that provides soothing, quick, and lasting pain relief without stinging, drying or burning."","length":792,"tagName":"p"},{"type":"text","content":""If it weren't for Gelclair, I don't know if I would have continued with chemo. It was that painful. Gelclair gave me relief when nothing e...